Lista de obras -

Advances in targeting signal transduction pathways

artículo científico publicado en 2012

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

artículo científico publicado en 2008

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells

artículo científico publicado en 2011

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

artículo científico publicado en 2010

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity ⬇️

artículo científico publicado el 1 de octubre de 2012

Emerging MEK inhibitors.

artículo científico publicado en 2010

Emerging Raf inhibitors.

artículo científico publicado en 2009

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy

artículo científico publicado en 2010

Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells

artículo científico publicado en 2014

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

artículo científico publicado en 2011

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

artículo científico publicado en 2011

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

artículo científico publicado en 2012

Novel approaches to target cancer initiating cells-eliminating the root of the cancer

artículo científico

Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells

artículo científico publicado en 2015

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

artículo científico publicado en 2012

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

artículo científico publicado en 2011

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

artículo científico publicado en 2011

Targeting prostate cancer based on signal transduction and cell cycle pathways.

artículo científico publicado en 2008

Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

artículo científico publicado en 2009

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

artículo científico publicado en 2012

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

artículo científico publicado en 2010

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

artículo científico publicado en 2011

Lista de obras de

Advances in targeting signal transduction pathways

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity ⬇️

Emerging MEK inhibitors.

Emerging Raf inhibitors.

Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy

Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

Novel approaches to target cancer initiating cells-eliminating the root of the cancer

Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Targeting prostate cancer based on signal transduction and cell cycle pathways.

Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.